Publications - Asgard Therapeutics

Cristiana F. Pires and Carlos-Filipe Pereira Cellular Reprogramming

Reprogramming Stars #6: A Venture Based in Cellular Reprogramming—An Interview with Dr. Cristiana Pires

In this interview, reprogramming Star Cristiana Pires unveils the career path that lead her to the stellar position of CEO and Co-founder at Asgard Therapeutics in this month issue of Cellular Reprogramming.

View publication

Rosa FF, Pires CF, Kurochkin I, Halitzki E, Zahan T, Arh N, Zimmermannova O, Ferreira AG, Li H, Karlsson S, Scheding S and Pereira CF. Science Immunology

Single cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells.

In this paper, we used single-cell transcriptomics to dissect successful reprogramming of human fibroblasts into induced cDC1-like cells and improved cDC1 reprogramming efficiency by 190-fold. We benchmarked the function of induced cDC1-like cells to naturally-occuring cDC1s and explored how PU.1, IRF8 and BATF3 engage the chromatin to induce the cDC1 fate in fibroblasts.

View publication

Zimmermannova O, Caiado I., Ferreira AG and Pereira CF. Frontiers in Immunology

Cell Fate Reprogramming in the Era of Cancer Immunotherapy.

In this review, we summarize current strategies for cancer immunotherapy, summarize technologies for generation of immune cells by cell fate reprogramming as well as highlight the future potential of inducing these unique cell identities in vivo, providing new and exciting tools for the fast-paced field of cancer immunotherapy.

View publication

Rosa FF, Pires CF, Zimmermannova O and Pereira CF. Bio-protocol

Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors.

In this paper, we provide a detailed direct cell reprogramming protocol to induce murine iDCs from mouse fibroblasts.

View publication

Pires CF, Rosa FF, Kurochkin I and Pereira CF. Frontiers in Immunology

Understanding and Modulating Immunity with Cell Reprogramming.

In this review, we summarize cell reprogramming concepts and experimental approaches, review current knowledge at the intersection of cell reprogramming with hematopoiesis, and propose how cell fate engineering can be merged to immunology, opening new opportunities to understand the immune system in health and disease.

View publication